Seeking Alpha

Salix Pharmaceuticals (SLXP +7.5%) gets a pop today after its Q3 EPS came in well ahead of...

Salix Pharmaceuticals (SLXP +7.5%) gets a pop today after its Q3 EPS came in well ahead of expectations and the drug developer raised its FY12 profit guidance for the third time this year. Sales of its key antibiotic drug Xifaxan jumped 43%, leaving analysts estimates in the dust. The company now expects an FY12 EPS of $3.13 on revenues of $735M, above the Street estimate of $2.89 on revenues of $739M.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector